Microsoft files a patent for a new innovative blood pressure monitor

By Catherine Sturman
Technology giants have been increasingly moving towards the healthcare sector, and Microsoft is no exception. From providing medical solutions for dia...

Technology giants have been increasingly moving towards the healthcare sector, and Microsoft is no exception.

From providing medical solutions for diabetes suffers, to the launch of new health wearables, such as Fitbits and Apple Watches, tech companies have sought to partner with health experts to deliver products and services which cater to the needs of its target audiences.

Microsoft has recently filed a patent for its new innovative blood pressure monitoring system, which could be set to revolutionise traditional medical tools. Instead of old-fashioned oscillometric blood pressure devices, Microsoft’s patent encompasses eyeglasses, which harness optical sensors to enable continuous monitoring, providing greater control to users.

Developed by Microsoft’s Research division, chief designers Christian Holz and Edward Wang have released a report detailing the advantages of the new product.

See also

Named Glabella, the head mounted device will be embedded with sensors, which will be placed at arterial locations to effectively measurer a user’s pulse waves, providing increased accuracy in comparison with traditional digital tools. The device will also work as an activity tracker by capturing essential data.

Through a global trial, the paper has revealed that the prototype will effectively measure pulse transit time and systolic blood pressure, to deliver accurate blood pressure readings, but interestingly not diastolic pressure, which is normally required to detect any cardiac abnormalities.

Noting that the eyeglasses are heavier than traditional eyewear, Microsoft will aim to build a lighter prototype and explore ways to develop the technology further.

Microsoft has ramped up its investment in healthcare, and has also recently partnered with Case Western Reserve University (CWRU) to further improve patient care.

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare